Hedley D, Rugg C, Musgrove E, Taylor I
J Cell Physiol. 1985 Jul;124(1):61-6. doi: 10.1002/jcp.1041240111.
We investigated the effects of the iron chelator desferrioxamine on the expression of transferrin receptors (TfR) by CCRF-CEM human T-cell leukaemia and B16 mouse melanoma cells growing in tissue culture. Desferrioxamine (DFOA) enhanced TfR expression when added in the dose range of 10(-5)-10(-4) to CCRF-CEM cells, but was toxic to these cells, the lower concentrations producing a slowing of cell growth with a build up in S-phase, while higher concentrations caused cell death with a block at the G1/S-phase interface. These toxic effects are compatible with its previously reported inhibition of the non-haem iron containing (M2) subunit of ribonucleotide reductase. In marked contrast, DFOA caused the growth of B16 melanoma cells to arrest in G1, without loss of cloning efficiency, and resulted in a fall in TfR expression to approximately 50% of control values. These results suggested that the effects of DFOA on TfR expression were linked to DNA synthesis rather than to a more generalised inhibition of iron-dependent cellular processes. It was subsequently found that inhibition of the M2 subunit of ribonucleotide reductase in CCRF-CEM cells with 5 X 10(-5) M hydroxyurea, which is not an iron chelator, also enhanced TfR expression, as did thymidine and cytosine arabinoside, which have different enzyme targets. By measuring cellular DNA and RNA content simultaneously it was shown that all of these agents caused unbalanced growth, i.e., inhibited DNA synthesis more than RNA synthesis. In contrast, 6-thioguanine was more inhibitory to RNA synthesis, and treatment with this drug caused a fall in TfR expression. Thus, although CCRF-CEM cells treated with DFOA show enhanced TfR expression, similar effects are also seen with other inhibitors of DNA synthesis, provided that RNA synthesis is allowed to continue. These results provide further evidence that the regulation of TfR expression by proliferating cells is specifically linked to DNA synthesis rather than to the iron requirements of other cellular processes.
我们研究了铁螯合剂去铁胺对在组织培养中生长的CCRF-CEM人T细胞白血病细胞和B16小鼠黑色素瘤细胞转铁蛋白受体(TfR)表达的影响。当以10^(-5)-10^(-4)的剂量范围添加到CCRF-CEM细胞中时,去铁胺(DFOA)增强了TfR的表达,但对这些细胞有毒性,较低浓度会导致细胞生长减慢,S期积累,而较高浓度会导致细胞死亡并在G1/S期界面处阻滞。这些毒性作用与其先前报道的对核糖核苷酸还原酶含非血红素铁(M2)亚基的抑制作用相符。与之形成显著对比的是,DFOA导致B16黑色素瘤细胞的生长在G1期停滞,而不丧失克隆效率,并导致TfR表达下降至对照值的约50%。这些结果表明,DFOA对TfR表达的影响与DNA合成相关,而非与对铁依赖性细胞过程的更广泛抑制相关。随后发现,用5×10^(-5) M羟基脲(一种不是铁螯合剂的物质)抑制CCRF-CEM细胞中的核糖核苷酸还原酶M2亚基,也会增强TfR的表达,胸苷和阿糖胞苷也有同样的效果,它们具有不同的酶作用靶点。通过同时测量细胞DNA和RNA含量表明,所有这些试剂都会导致生长失衡,即抑制DNA合成的程度超过RNA合成。相比之下,6-硫鸟嘌呤对RNA合成的抑制作用更强,用这种药物处理会导致TfR表达下降。因此,尽管用DFOA处理的CCRF-CEM细胞显示出TfR表达增强,但其他DNA合成抑制剂也会产生类似效果,前提是允许RNA合成继续。这些结果进一步证明,增殖细胞对TfR表达的调节与DNA合成特异性相关,而非与其他细胞过程的铁需求相关。